Evidence map›Paper›PMID 32849848›Full record

ArticleFrontiers in genetics2020

Beyond Single Nucleotide Polymorphisms:

Daniel A Brazeau, Kristopher Attwood, Calvin J Meaney, Gregory E Wilding, Joseph D Consiglio, Shirley S Chang, Aijaz Gundroo, Rocco C Venuto, Louise Cooper, Kathleen M Tornatore

Open access · goldAbstract read
In one paragraph

Article in Frontiers in genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Daniel A BrazeauDepartment of Pharmacy Practice, Administration and Research, School of Pharmacy, Marshall University, Huntington, WV, United States.
Kristopher AttwoodDepartment of Biostatistics, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY, United States.
Calvin J MeaneyImmunosuppressive Pharmacology Research Program, Translational Pharmacology Research Core, NYS Center of Excellence in Bioinformatics and Life Sciences, Buffalo, NY, United States.
Gregory E WildingDepartment of Biostatistics, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY, United States.
Joseph D ConsiglioDepartment of Biostatistics, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY, United States.
Shirley S ChangJacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, United States.
Aijaz GundrooJacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, United States.
Rocco C VenutoJacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, United States.
Louise CooperImmunosuppressive Pharmacology Research Program, Translational Pharmacology Research Core, NYS Center of Excellence in Bioinformatics and Life Sciences, Buffalo, NY, United States.
Kathleen M TornatoreImmunosuppressive Pharmacology Research Program, Translational Pharmacology Research Core, NYS Center of Excellence in Bioinformatics and Life Sciences, Buffalo, NY, United States.
University at Buffalo, State University of New York · USJacobs (United States) · USErie County Medical Center · USMarshall University · US

Funding

Age and Race Influences on Immunosuppression after Renal TransplantR01AG056392 · NIA · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI TORNATORE, KATHLEEN M · 2018 to 2022
$3.5M
Genomic and Cellular Markers and Chronic Renal Allograft FunctionR21DK077325 · NIDDK · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI TORNATORE, KATHLEEN M · 2009 to 2010
$427k
NIA NIH HHS R01 AG056392NIDDK NIH HHS R21 DK077325
6 · The paper itself

Abstract

Interpatient variability in tacrolimus pharmacokinetics is attributed to metabolism by cytochrome P-450 3A5 (CYP3A5) isoenzymes and membrane transport by P-glycoprotein. Interpatient pharmacokinetic variability has been associated with genotypic variants for both

Indexed as

ABCB1 haplotypesCYP3A5 genotypesimmunosuppressionpharmacogenomicsracerenal transplantationtacrolimustacrolimus pharmacokinetics

Identifiers

PMID32849848
PMCPMC7433713
OpenAlexW3048874500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.